Semnur Pharmaceuticals, Inc. (SMNR)

Semnur Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	0.02	0.01	0.01	0.03
Cash & Short-Term Investments	0.02	0.01	0.01	0.03
Cash Growth	66.67%	-	-57.14%	-
Prepaid Expenses	0.58	0	0	0.05
Other Current Assets	-	5.98	-	-
Total Current Assets	0.6	6	0.01	0.07
Property, Plant & Equipment	0.75	0.69	0.69	0.69
Total Assets	1.35	6.68	0.7	0.76
Accounts Payable	5.91	-	-	-
Accrued Expenses	0.74	0.04	0.9	0.17
Short-Term Debt	3.52	-	-	-
Other Current Liabilities	-	-	-	0.02
Total Current Liabilities	10.17	0.04	0.9	0.2
Long-Term Debt	11.93	49.43	37.9	35.4
Total Liabilities	22.1	49.47	38.8	35.6
Common Stock	0.02	0.02	0	0
Additional Paid-In Capital	255.03	72.58	72.6	72.6
Retained Earnings	-275.8	-115.38	-110.69	-107.43
Total Common Equity	-20.75	-42.78	-38.09	-34.83
Shareholders' Equity	-20.75	-42.78	-38.09	-34.83
Total Liabilities & Equity	1.35	6.68	0.7	0.76
Total Debt	15.45	49.43	37.9	35.4
Net Cash (Debt)	-15.43	-49.42	-37.89	-35.37
Net Cash Per Share	-0.08	-0.25	-0.24	-0.22
Filing Date Shares Outstanding	230.21	160	160	160
Total Common Shares Outstanding	230.21	160	160	160
Working Capital	-9.57	5.96	-0.88	-0.12
Book Value Per Share	-0.09	-0.27	-0.24	-0.22
Tangible Book Value	-20.75	-42.78	-38.09	-34.83
Tangible Book Value Per Share	-0.09	-0.27	-0.24	-0.22
Machinery	0.03	0.03	0.03	0.03
Construction In Progress	0.75	0.69	0.69	0.69

Source: S&P Global Market Intelligence. Standard template. Financial Sources.